Rossari Biotech collects Rs 149 crore from anchor investors ahead of IPO

Rossari Biotech's initial share-sale will end four months of inactivity in the IPO markets. SBI Cards & Payment Services was the last company to float IPO in March.

Published On 2020-07-14 03:45 GMT   |   Update On 2020-07-14 03:45 GMT

New Delhi: Specialty chemicals manufacturer Rossari Biotech on Friday said it has raised Rs 149 crore from anchor investors ahead of its initial share-sale that opens on Monday.The anchor investors include Abu Dhabi Investment Authority, HDFC Mutual Fund, Axis Mutual Fund, ICICI Prudential Mutual Fund, SBI Mutual Fund, Sundaram Mutual Fund, HDFC Life Insurance Company, and Goldman Sachs...

Login or Register to read the full article

New Delhi: Specialty chemicals manufacturer Rossari Biotech on Friday said it has raised Rs 149 crore from anchor investors ahead of its initial share-sale that opens on Monday.

The anchor investors include Abu Dhabi Investment Authority, HDFC Mutual Fund, Axis Mutual Fund, ICICI Prudential Mutual Fund, SBI Mutual Fund, Sundaram Mutual Fund, HDFC Life Insurance Company, and Goldman Sachs India.

In a statement, the company said it has raised Rs 148.87 crore in anchor allotment and has finalized allocation of 35,02,940 shares to 15 institutional investors at Rs 425 per share, which is the upper limit of the price band for the IPO.

The company has fixed a price band of Rs 423-425 per equity share for its initial public offer (IPO) which will be open for public subscription from July 13-15.

Rossari Biotech's initial share-sale will end four months of inactivity in the IPO markets. SBI Cards & Payment Services was the last company to float IPO in March.

Rossari Biotech's IPO comprises fresh issuance of shares worth Rs 50 crore and the sale of 1,05,00,000 equity shares by the company's promoters through offer-for-sale route.

At the upper end of the price band, the IPO size is about Rs 496 crore.

The company has already raised Rs 100 crore in pre-IPO placement.

Net proceeds from the issue will be utilized for funding working capital requirements, repaying certain debt availed by the company, and for general corporate purposes.

Axis Capital and ICICI Securities are the merchant bankers for the share-sale. The equity shares will be listed on the NSE and BSE.

The company, which filed its draft papers with Sebi in December 2019, received clearance from the regulator in February to launch the IPO.

Rossari Biotech is a specialty chemical manufacturing firm with a focus on home and personal care, performance chemicals, textile specialty chemicals, and animal health and nutrition products.

Apart from India, it has operations in 17 countries, including Vietnam, Bangladesh, and Mauritius.

Read also: Rossari Biotech to launch Rs 500-crore IPO soon

Tags:    
Article Source : PTI

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News